Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer selects candidate for development in asthma
The selection of the candidate by Pfizer constitutes a milestone in the collaboration between the two companies which will result in Rigel receiving a $5 million payment. The
The selection of the candidate by Pfizer constitutes a milestone in the collaboration between the two companies which will result in Rigel receiving a $5 million payment. The
The new data show Rasilez provides significant blood pressure reductions, sustained over 24 hours. Meanwhile, new data on Exforge show that its dual mechanism of action lowered systolic
Currently Takahashi is senior vice president and executive officer, executive vice president of Information & Telecommunication Systems Group and chief executive officer (CEO) of Platform Business, Information &
The trial will include patients with resistant strains of disease including methicillin-resistant Staphylococcus aureus (MRSA). “We have enrolled more than 1,800 patients overall and expect to have more
The single center phase IIa study is a placebo-controlled, parallel group study designed to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day dosing cycles in obese
Cesamet is a synthetic version of cannabis that is thought to interact with the cannabinoid receptor, CB1, which is present throughout the nervous system and is involved in
The newly-released data indicates that at 29 to 34 months after initial treatment, there was highly significant symptomatic improvement. There were no serious safety issues reported in individuals
The trial, targeted to commence in the third quarter of this year, is a 12 month, double blind, placebo-controlled trial and will enroll up to 215 patients with
In the study, which enrolled 887 patients, 73% of patients receiving Lexiva/ritonavir maintained suppression of viral replication after 48 weeks of dosing, compared with 71% of patients receiving
The agency determined that indiplon 5mg and 10mg capsules are 'approvable' but considered the all-important 15mg extended release version of the drug to be 'not approvable.' The rejection